Basic Information
Menveo Powder and Solution for Solution for Injection
INJECTION, POWDER, FOR SOLUTION
Regulatory Information
SIN14083P
January 20, 2012
Prescription Only
Therapeutic
INTRAMUSCULAR
August 10, 2023
June 3, 2025
XJ07AH08
Company Information
GLAXOSMITHKLINE PTE LTD
GLAXOSMITHKLINE PTE LTD
Active Ingredients
(MenA Lyo) Meningococcal Group A oligosaccharide conjugated to CRM197 protein
Strength: 10 microgram conjugated to 16.7-33.3 microgram
Strength: 5 microgram conjugated to 5.6-10 microgram
Strength: 5 microgram conjudated to 7.1-12.5 microgram
Strength: 5 microgram conjugated to 3.3-8.3 microgram
Detailed Information
Contraindications
**4.3 Contraindications** Hypersensitivity to the active substances or to any of the excipients of the vaccine, including diphtheria toxoid (CRM197), or a life-threatening reaction after previous administration of a vaccine containing similar components (see section 4.4 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
Indication Information
**4.1 Therapeutic indications** Menveo is indicated for active immunization of children (from 2 months of age), adolescents and adults at risk of exposure to _Neisseria meningitidis_ groups A, C, W-135 and Y, to prevent invasive disease. The use of this vaccine should be in accordance with official recommendations.